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Forkhead-box transcription factor 1 affects
the apoptosis of natural regulatory T cells
by controlling Aven expression
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Abstract
Background: Regulatory T (Treg) cells play important roles in autoimmune diseases, cancer, and organ transplantation.
Forkhead box protein o1 (Foxo1) and IL-7Rα(CD127) are closely related to the homeostasis of Treg cells. However, the
mechanism underlying Treg proliferation and activation remains unclear. Here, we evaluated how the over-expression
of Foxo1 affects Treg cell proliferation via intracellular signaling. nTreg cells were transfected separately with Foxo1 and
Aven small-interfering RNA (siRNA) or over-expression plasmid. The expression of signaling pathway genes and CD127
was confirmed using RT-qPCR and western blot analysis. The expression of cell surface molecules and apoptosis was
confirmed by Flow Cytometry 3-(4, 5-Dimethylthiazol-2-yl) 2,5- diphenyltetrazolium bromide for cell proliferation assays.
Results: Foxo1 strengthened the proliferative ability of Treg cells by activating IL-7/CD127 signaling. In addition, Foxo1
suppressed Treg cell apoptosis by regulating Aven expression.
Conclusions: The results in this study indicated that Foxo1 is a positive regulatory factor for the proliferation and
activity of Treg cells. Foxo1 might be a potential target for the activation of nTreg cells in vivo and in vitro.
Keywords: Treg cells, Foxo1, Aven, Apoptosis
Background
Regulatory T cells (Tregs) are a subpopulation of T cells
that are thought to be derived from the same lineage as
naïve CD4 cells due to the same expression of CD4 and
CD25 [1]. In addition, Tregs express the biomarker
forkhead box P3 (Foxp3) transcription factor [2, 3]. It
has been reported that TGF-β is essential for Tregs to
differentiate from naïve CD4 cells and is important in
maintaining Treg homeostasis [4]. Tregs can be divided
into two subsets: naturally occurring or thymus-derived
Treg (nTreg) cells and T regulatory type 1(Tr1) cells.
Tregs play an important role in autoimmune diseases,
cancer, and organ transplantation [5–7].
Tregs are the front-runners in the race for therapeutic
immune-regulation due to their ability to suppress
effector T cells, which are known to play an important
role in preventing autoimmunity [5, 8]. In recent years,
it has been reported that nTregs can also effectively
prevent the rejection of transplanted allografts in experi-
mental models [9, 10]. Naturally, nTregs were used in
hematopoietic stem cell transplantation to inhibit graft-
versus-host disease (GVHD) [11, 12]. However, the
widespread clinical use of Tregs has been limited by the
low number of these cells in the periphery and immune
homeostas [13]. Therefore, there is a great need for
understanding the mechanism of proliferation and
immune homeostasis in nTregs to prevent the rejection
of transplanted allografts.
Interleukin-7 (IL-7) is a hematopoietic growth factor
that plays a critical role in regulating the homeostasis of
T cells [14, 15]. The control of IL-7 signaling is mainly
dependent on the IL-7 receptor (IL-7R), which is a
heterodimer that consists of the IL-7 receptor alpha
(IL-7Rα, CD127) and common gamma chain receptor
[16]. Therefore, CD127 plays a key role in modulating
the homeostasis of T-cells. However, the molecular
mechanism by which CD127 controls Treg cell prolif-
eration and homeostasis remains unknown.
Forkhead box protein o1 (Foxo1) is a transcription factor
and is characterized by a distinct fork head domain. It was
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shown that Foxo1-deficient mice developed a fatal inflam-
matory disorder [17]. Indeed, a growing body of research
suggests that Foxo1 plays an important role in the immune
system, including peripheral T-cell homeostasis [18]. Foxo1
can modulate the expression of IL-7Rα, which is expressed
in T-cells [19]. Furthermore, Foxo1 can regulate the ex-
pression of Aven [17], which is an adaptor protein that has
been implicated in anti-apoptotic signaling [20]. Therefore,
we speculated that Foxo1 modulates Treg cell homeostasis
and functions via CD127 and Aven.
In the present study, we found that Foxo1 over-expres-
sion resulted in Treg cell proliferation by activating IL-7/
CD127 signaling. In addition, Foxo1 over-expression sup-
pressed Treg cell apoptosis by regulating Aven expression.
Taken together, these data suggest that Foxo1 is required
for Treg cell proliferation and apoptosis by controlling
CD127 and Aven expression.
Methods
Mice
Foxp3-GFP mice were obtained from Jackson Laboratories
and were bred according to the Experimental Animal
Centre of the Third Military Medical University and
housed in a specific pathogen-free facility. Mice ages 6–8
weeks were used for the experiment. The experimental
protocol was approved by the Ethics Committee of the
Third Military Medical University.
Sorting and flow cytometry
Spleen lymphocytes were isolated from Foxp3-GFP mice.
The mice were killed by neck dislocation after following
4.5 mg/kg pentobarbital sodium (Sigma-Aldrich, St.
Louis, MO, USA) via intraperitoneal injection in sterile
environments. The spleen was removed for broking, and
the cell lymphocyte suspension was obtained. Next, the
cells were separated by lymphocyte separation liquid
(TBD, Tianjin, China), and the cells were resuspended in
FACS buffer (PBS) containing 1% BSA and 2% FBS for
sorting by FACSCanto (BD Bioscience). The sorted cells
were cultured in 1640 medium containing 20% FBS for
further experiments.
Cell staining was performed in FACS buffer (PBS) con-
taining 1% BSA and 2% FBS. The cells were stained with
phycoerythrin-conjugated anti-mouse ICOS antibody
(ebioscience, San Diego, CA, USA), Allophycocyanin
conjugated anti-mouse CD127 antibody (BD Biosciences,
San Jose, CA, USA), phycoerythrin-conjugated anti-
mouse CD103 antibody (BD Biosciences) antibody or
Allophycocyanin conjugated anti-mouse CD25 (Biole-
gend, San Diego, CA, USA) antibody at 4 °C for 30 min
and were then washed with PBS containing 2% BSA or
FBS (wt/vol). Cells were collected using a FACSCanto
(BD Bioscience) and analyzed by FlowJo.
Plasmid construction and transient transfections
Invitrogen provided Foxo1 and Aven small hairpin RNA
(shRNA). With reference to the target gene, mouse
Foxo1 Sense 5′ -GGG GTA TGG CCG AAG CGC CCC
AGG -3′, antisense 5′- TTA GCC TGA CAC CCA
GCT GAG AGC -3′, mouse Aven Sense5′ –GGG GTA
TGT TCG AAG CAC GT -3′, antisense 5′-TCA GGA
AAT CAT GCT GTA GAG CA-3′. A series of chem-
ically synthesized oligonucleotides was spliced by poly-
merase chain reaction (PCR) to obtain gene sequences,
and these sequences were then inserted into the pCMV5
vector [21]. The integrity of all constructs was confirmed
by DNA sequencing. Using the Nucleofector Program
U-25, 2 mg of plasmid was transfected into 1 × 106 cells
using the Amaxa Basic Nucleofector kit (Lonza,
Switzerland), according to the manufacturer’s protocol.
Quantitative PCR
Total RNA was extracted in Trizol LS reagent (Takara,
Japan) and reverse-transcribed using a PrimeScript RT
reagent kit (Takara). Next, cDNA was amplified (38 cy-
cles of 95 °C for 20 s, 62 °C for 15 s, and 72 °C for 20 s)
with SYBR qPCR SuperMix (Novoprotein, Shanghai,
China) according to the manufacturer’s instructions,
using gene-specific sets of primers: f for mouse Foxo1
gene, 5′ – TGT TTG ATT CAT TTC CTT TGG T -3′
and 5′ –TGA TTT TCT CCG CTT ACT GTT G -3′;
mouse CD127 gene, 5′-AAA AGT AAA GCA TGA
TGT GGC C -3′ and 5′ –TTG AAG TAA TCG TTA
TGG GGA A -3′; mouse Icos gene, 5′ – CAT TCC
CAA CAC GAA CAC CTA A -3′ and 5′ –TCT TCA
CCC CCA GAA AAC ACA G -3′; mouse Aven gene,
5′- GGG ACC AGG AAC CAG AAA AAG A -3′ and
5′ – TAC ACA GAA GGC AAC CAG CAT T -3′;
mouse IL-2 gene, 5′- GAT GAA CTT GGA CCT CTG
CG -3′ and 5′- AGG GCT TGT TGA GAT GAT GC
-3′; mouse IL-4 gene, 5′- CAT CCT GCT CTT CTT
TCT CG -3′ and 5′- CCT TCT CCT GTG ACC TCG
TT -3′; mouse IL-7 gene, 5′- GTT ATG GCA AAG
CCA GAG CG -3′ and 5′- TGC GGG AGG TGG GTG
TAG TC-3′; mouse IL-14 gene, 5′- CCC CTT CTG
TCC AGC CAC TC -3′ and 5′- TCC CGT CTT CG
TCC AA TCT-3′. mouse Bcl2 gene, 5′-GC TAC CGT
CGT GAC TTC GC -3′ and 5′- ATC CCA GCC TCC
GTT ATC C-3′. For each gene, the mRNA level was
normalized against GAPDH expression in the respective
cDNA preparation. Controls were set to 1.0, and each
gene induction was calculated as the fold difference
compared to controls. Each reported expression value
represents the average of 3 independent experiments.
Western blot analysis
Cells were collected and dissolved in RIPA buffer (1%
sodium deoxycholate, 1% Triton X-100, 150 mM NaCl,
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0.1% SDS, 10 mM Tris–HCl pH 7.2), Total proteins were
separated on 10% SDS-PAGE and transferred onto polyvi-
nylidene fluoride (PVDF) membranes by electroblotting
for 1 h (110 V). The PVDF membranes (Millipore, MA,
USA) were blocked in Tris- buffered saline containing 5%
nonfat milk and incubated with primary antibody in Tris-
buffered saline and Tween (TBST) with 5% nonfat milk
over-night at 4 °C. Primary antibodies against the follow-
ing proteins were used: Erk1/2, p-Erk1/2, Akt, p-Akt,
Stat5, p-Stat5, Aven and GAPDH (Abcam, Cambridge,
MA, USA); Foxo1, p-Foxo1 (Cell Signaling Technology,
Danvers, MA,USA), CD127 (Biolegend) and Bcl2 (Pepro-
Tech, Rocky Hill, NJ,USA). The membranes were washed
three times for 5 min with TBST and were then incubated
with the appropriate secondary antibody in TBST with 5%
nonfat milk for 1 h at room temperature. Protein binding
was visualized using an enhanced chemiluminescence kit
(Pierce) and X-ray films.
Chromatin immunoprecipitation assays and real-time PCR
Chromatin immunoprecipitation assays were performed
using a ChIP assay kit (Merck Millipore, Darmstadt,
Germany) according to the manufacturer’s protocol.
Cells (1 × 106) were fixed in formaldehyde (1%) in
medium and were then incubated for 10 min at room
temperature. The pellets were washed with cold PBS,
and the fixed cells were sonicated (15 cycles of 30-s son-
ication with 60 s of cooling in an ice-water bath) using a
MISONIX XL-2000 (Qsonica, Newtown, CT, USA) at a
power setting of 15, to shear the DNA in SDS lysis
buffer. After preclearing by shaking with protein A or G,
these lysates were incubated with 4 mg of antibodies or
normal IgG at 4 °C for 16 h. The immuno-precipitated
DNA was purified using a QIAquick PCR purification
kit (Qiagen, Germany) according to the manufacturer’s
protocol. Next, the purified DNA was used as a template
for semi-quantitative and real-time PCRs with specific
pairs of primers: for the mouse Aven promoter, 5′- TTT
GAG CCA AGG TTC TAA CAA A -3′ and 5′ – CCA
ATA CTA ACA TCA CGG AGG G -3′
Detection of cell apoptosis by flow cytometry
Cell apoptosis was detected using the Annexin V-FITC/PI
apoptosis detection kit. SH-SY5Y cells were seeded into 6-
well culture plates (4.0 × 103 cells/cm2) and cultured for
24 h. The medium was removed after these groups were
treated, and the cells were rinsed once with 0.1 M PBS.
Cells were passaged using 0.25% trypsinization for 2 min
Fig. 1 Detection of Foxo1 and CD127 after knockdown and over-expression of Foxo1 in Treg cells. a Expression of mRNA and protein of Foxo1
and CD127 in Treg cells, 48 h after transfection with Foxo1 siRNA. b Expression of mRNA and protein of Foxo1 and CD127 in Treg cells 48 h after
transfection with over-expression plasmid of Foxo1. Treg cells stimulated with anti-CD3 (0.01 μg/ml) and anti-CD28 (1.0 μg/ml) in medium during
culture. Data are presented as the mean + standard deviation (SD). *P < 0.01; **P < 0.005
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and collected in centrifuge tubes. Cells were centrifuged at
1500 r/min for 5 min, and the supernatants were dis-
carded. Binding Buffer (200 μL) was added into each tube
and vortexed. Annexin V-FITC (5 μL) was added for
10 min at room temperature in the dark, and the tubes
were centrifuged at 1000 r/min for 5 min. Supernatants
were discarded, and 200 μL Binding Buffer was added to
resuspend the cells. PI (5 μL) was added to the mixture
for testing.
MTT assay
Cells were cultured in a 96-well culture plate at a density
of 1 × 104 cells/cm2 for 1–6 days. Each group was
pretreated with different reagents for 4 h. Reagents and
40 μM TBHP were added, and 24 h later, the media were
removed. DMEM (100 μL) with 10% MTT was added to
each well and kept at 37 °C; 4 h later, the media was
discarded. DMSO was added and placed on a shaker in
the dark for 10 min. The absorption was measured at
570 nm using a Bio-Rad 400 microplate reader (Bio-Rad,
Hercules, CA, USA). Experiments were repeated 3
times.
Statistical analyses
All data were analyzed using the SPSS 17.0 statistical
software (version 17.0, Chicago, IL, USA). The data are
presented as the mean ± s.d. of three independent ex-
periments; Student’s t-test was used for comparisons.
P < 0.01 was considered significant.
Results
Foxo1 regulates CD127 expression in Treg cells
To investigate the role of Foxo1 on IL-7Rα expression in
Treg cells, Treg cells were transfected with Foxo1 siRNA
or control siRNA. We found that Foxo1 mRNA expression
decreased by more than 50% when using Foxo1 siRNA
compared to control siRNA (Fig. 1a). Consistent with these
findings, Foxo1 protein expression was downregulated in
Fig. 2 Detection of cell surface molecules and signaling pathway molecules after knockdown and over-expression of Foxo1 in Treg cells.
a, Representative expression of the Foxo1, CD127, CD103, ICOS, Foxp3 or CD25 in Treg cells 48 h after transfection with Foxo1 siRNA by flow
cytometry (broken black line: isotype, green line: control, red line: Foxo1 siRNA). b Representative expression of the Foxo1, CD127, CD103, ICOS,
Foxp3 or CD25 in Treg cells 48 h after transfection with over-expression plasmid of Foxo1 by flow cytometry (broken black line: isotype, green
line: control, red line: Foxo1 over-expression). c Detected of Median Fluorescence Intensity (MFI) for CD127 in Treg cells 48 h after transfection
with Foxo1 siRNA and Foxo1 over-expression plasmid by flow cytometry. d Representative western blot of p-Erk1/2, total Erk1/2, p-Akt, total Akt,
p-Stat5, total Stat5, p-Foxo1 and total Foxo1 in Treg cells 48 h after transfection with Foxo1 siRNA and over-expression plasmid of Foxo1, GADPH
was used as a control. Treg cells stimulated with anti-CD3 (0.01 μg/ml) and anti-CD28 (1.0 μg/ml) in medium during culture. e Expression of
mRNA for IL-2, IL-4, IL-7 and IL-15 in Treg cells, 48 h after transfection with Foxo1 siRNA and Foxo1 over-expression plasmid. All experiments were
repeated at least three times. **P < 0.005, n.s: no significance
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Treg cells that were treated with Foxo1 siRNA compared
with control siRNA (Fig. 1a). Unexpectedly, CD127 protein
expression was downregulated in Treg cells-treated with
Foxo1 siRNA compared with control siRNA (Fig. 1a). Con-
versely, Foxo1 over-expression increased the expression of
CD127 in Treg cells (Figs. 1b and 2b), which suggested that
Foxo1 plays an important role in CD127 expression.
Foxo1 controls Treg cell proliferation by regulating
CD127 expression
To test the role of Foxo1 in activating Treg cells, we
detected CD103 and inducible co-stimulatory molecule
(ICOS) by FCM, they have been described to identify
activated Treg cells [22, 23]. CD127 was also detected by
FCM in Treg cells. We found that CD127, CD103 and
ICOS showed little change in Treg cells treated with
Foxo1 siRNA and control siRNA, and the Median Fluor-
escence Intensity (MFI) of CD127 showed no significant
difference between Foxo1 siRNA-treated cells and con-
trol siRNA cells (Fig. 2c). However, CD127, CD103 and
ICOS expression was significantly increased in Foxo1
over-expression Treg cells, and the MFI of CD127 in
Foxo1 over-expressed cells was 2.6 times higher than
control (Fig. 2c). CD25 and Foxp3 showed little change
in Treg cells in both Foxo1 knockdown and over-
expressed cells (Fig. 2a, b). In addition, intracellular
signaling molecules associated with the activity of Treg
cells, including p-Erk1/2, p-Akt, p-Foxo1 and p-Stat5,
demonstrated no change (Fig. 2d). These findings
suggested that Treg cells can be activated by over-
expression Foxo1. Cytokines that affect Treg cell
activities, such as IL-2, IL-4, IL-7 and IL-15 [24], were
detected using quantitative PCR. However, at the mRNA
level of the genes, there were no differences when Foxo1
was over-expressed and knocked down (Fig. 2e).
Next, Treg cells were stimulated with CD3, CD28 and
IL-7 to activate cell proliferation, and the cell prolifera-
tion rate was detected using ELISA. We found that the
cell proliferation rate was higher in the Foxo1 over-
expression cells than in the Foxo1 siRNA cells (Fig. 3a).
But the cell proliferation rate decreased following
treatment with the anti-CD127 antibody in the Foxo1
over-expression cells (Fig. 3a). Similarly, Treg cells were
incubated without IL-7, the cell proliferation rate de-
creased (Fig. 3a), which suggested that Foxo1 controls
Treg cell proliferation by regulating IL-7/CD127
signaling.
Foxo1 controls Treg cell apoptosis by regulating Aven
expression
Treg cells were transfected with Foxo1-plasmid prior to
incubation with CD3, CD28 and IL-7, and apoptosis was
measured according to the instructions of the PI-Annexin
V apoptosis detection kit. We found that Foxo1 over-
expression inhibited apoptosis (Fig. 3b). Conversely, cell
apoptosis was enhanced in Treg cells after transfection
Fig. 3 Proliferation and apoptosis after knockdown or over-expression of Foxo1 in Treg cells. a Treg cells growth were measured for 6 days using
a MTT assay. Treg cells of every group (control, Foxo1-plasmid, Foxo1-RNAi and Foxo1-plasmid + CD127) except Foxo1-plasmid (no IL-7) was
stimulated with anti-CD3 (0.01 μg/ml), anti-CD28 (1.0 μg/ml) and IL-7 (0.03 μg/ml) during culture, and anti-CD3 and anti-CD28 was only added in
the Foxo1-plasmid (no IL-7) group. In addition, anti-CD127 (1:500) was added to the Foxo1-plasmid + CD127 group. These results are presented as
the mean ± s.d. of the values obtained in three independent experiments. b Representative result of apoptosis in Treg cells based on the above
groups 48 h after stimulation
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with Foxo1 siRNA (Fig. 3b). However, IL-7 or CD127
demonstrated no apoptotic role in the presence of Foxo1
(Fig. 3b), suggesting that Foxo1 inhibits Treg cell apop-
tosis via other signaling pathways. In view of the opinion
that Foxo1 may regulate the expression of the anti-
apoptotic protein Aven [17], we tested the hypothesis that
Foxo1 inhibits Treg cell apoptosis by regulating Aven
expression. We first observed that Foxo1 can bind to the
promoter of Aven as assessed by the Chip assay (Fig. 4a).
Furthermore, we found that Aven mRNA expression was
inhibited in Treg cells treated with Foxo1 siRNA com-
pared with control (Fig. 4b). Conversely, Foxo1 over-
expression increased the mRNA levels of Aven in Treg
cells (Fig. 4b). Consistent with these findings, the protein
expression of Aven showed the same trend at the mRNA
level (Fig. 4c). This finding indicated that Foxo1 regulates
Aven expression. The IL-7/CD127 axis is important for T-
cell homeostasis, which can be also mediated by Bcl2. We
detected the mRNA and protein levels of Bcl2 when Aven
was over-expressed and knocked down, whereas at the
mRNA and protein levels, there were no differences
between the conditions (Fig. 4c,d). Bcl2 might be not
regulated by Foxo1.
To detect the role of Aven in Treg cell apoptosis, Treg
cells were transfected with Aven siRNA or control
siRNA. Compared to Treg cells that were treated with
control siRNA, Aven expression was downregulated in
Treg cells treated with Aven siRNA at the mRNA and
protein levels (Fig. 5a-b). The flow cytometry results
showed that apoptosis was enhanced in Treg cells trans-
fected with Aven siRNA (Fig. 5c). When Aven was over-
expressed in Treg cells, we found that Aven expression
was upregulated at the mRNA and protein levels
(Fig. 5a-b) and that cell apoptosis was attenuated
(Fig. 5c), suggesting that Aven has anti-apoptotic proper-
ties in Treg cells. Furthermore, Treg cells are mainly
divided into two subgroups: nTreg and iTreg. We also
investigated the apoptosis of iTregs with Aven over-
expression and knockdown. These results indicated that
iTreg cells were similar with nTreg cells, such that
Fig. 4 Detection of Aven after knockdown and over-expression of Foxo1 in Treg cells. a Level of Foxo1 enrichment at the Aven gene promoters
in Treg cells in which Foxo1 was knocked down and over-expressed. Expression of the (b) mRNA and (c) protein of Foxo1 and Aven in Treg cells
48 h after transfection with Foxo1 siRNA and over-expression. Expression of the (c) protein and (d) mRNA of Bcl2 in Treg cells 48 h after transfection
with Foxo1 siRNA and over-expression. Cells was stimulated with anti-CD3 (0.01 μg/ml), anti-CD28 (1.0 μg/ml) and IL-7 (0.03 μg/ml) during culture.
Data are presented as the mean + standard deviation (SD). *P < 0.01; **P < 0.005, ***P < 0.001
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apoptosis in both cell types could be regulated by Aven
(Fig. 5c).
Discussion
The forkhead box (Fox) family genes have important
functions in many biological processes in human and
mice. The mutations of Fox genes caused many human
diseases, such as glaucoma, cancer, language disorders
and immune diseases [25]. Foxn1, a member of the Fox
family, involved in the differentiation and development
of human central nervous system [26], and palys important
roles for the differentiation and growth of T cell. Alter-
ations of Foxn1 result in the failure of generating mature
and functional thymocytes [27].
Foxo1 was also an important regulatory factor for the
differentiation and function of T cells [28]. In the
present study, we showed that Foxo1 activated the IL-7/
CD127 signaling pathway, resulting in increased Treg
proliferation. In addition, Foxo1 activated Aven expres-
sion, which plays an important role in cell apoptosis in
Treg cells, suggesting that Foxo1 inhibits Treg cell
apoptosis via Aven expression. These results indicated
that Foxo1 plays a key role in controlling Treg cell
proliferation and apoptosis by regulating CD127 and
Aven expression.
Many studies have shown that Foxo1 plays an important
role in T-cell homeostasis [19, 29]. Foxo1 regulates the
expression of CD127 by binding to the promoter of the
CD127 gene, and deletion of the Foxo1 gene can block
Fig. 5 Detection of apoptosis after knockdown and over-expression of Aven in Treg cells. Expression of the (a) mRNA and (b)protein of Aven in
Treg cells 48 h after transfection with Aven siRNA or over-expression plasmid of Foxo1. c Representative result of apoptosis in nTreg and iTreg
cells 48 h after transfection with Aven siRNA or over-expression plasmid of Foxo1. Treg cells were stimulated with anti-CD3 (0.01 μg/ml) and
anti-CD28 (1.0 μg/ml) in medium during culture. Data are presented as the mean + standard deviation (SD). ***P <0.001
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the expression of CD127 in T-cells [19, 29]. In this study,
we found that Foxo1 regulates CD127 expression in Treg
cells. This result is consistent with the result obtained in
previous reports. Activation of the IL-7/CD127 signaling
pathway can promote Treg cell proliferation. Therefore,
Foxo1 is involved in the regulation of Treg cell prolifera-
tion by regulating CD127.
In addition, we found that Foxo1 regulates cell apoptosis
in Treg cells. However, CD127 was confirmed to not be
involved in the cell apoptosis in Treg cells. Therefore,
Foxo1 regulates other molecules to inhibit cell apoptosis.
Aven is a novel molecule and can bind to the proapoptotic
APAF-1 protein to prevent the oligomerization of APAF-1
in the intrinsic apoptosis pathway [30]. Recently, It was
shown that Aven contributes to the anti-apoptotic proper-
ties of this protein [20]. We found that Foxo1 can regulate
Aven expression in Treg cells, which inhibits cell apop-
tosis. These data indicated that Foxo1 is involved in the
regulation of Treg cell apoptosis via Aven.
In conclusion, we demonstrated that Foxo1 over-
expression in the Treg cells results in a significant
enhancement of cell proliferation due to the activation
of the IL-7/CD127 signaling pathway. In addition, Foxo1
over-expression in Treg cells inhibits cell apoptosis by
regulating Aven expression. Collectively, Foxo1 is
required for Treg cell proliferation and apoptosis via
CD127 and Aven expression.
Conclusions
Our results suggest that Foxo1 is a positive regulatory fac-
tor for nTreg cell activation. It promotes the proliferation
of Treg cells and inhibits apoptosis via the Aven signaling
pathway. These data suggest that Foxo1 might be a prom-
ising target for activating nTreg cells in vivo and in vitro.
Basic and clinical research of treatment drugs provides a
useful reference.
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